Is erectile dysfunction a sign of heart disease?

Erectile dysfunction (ED) is frequently the first detectable sign of systemic vascular disease, and in men who go on to develop heart disease it typically precedes a cardiac event by 3–5 years. The penile arteries are smaller than coronary arteries, so atherosclerosis affects them earlier. Any man under 60 with new or worsening ED — without an obvious psychological explanation — should have a cardiovascular risk assessment, not just a prescription.

What are the most common causes of erectile dysfunction?

The most common causes are vascular (atherosclerosis, hypertension, dyslipidaemia), metabolic (type 2 diabetes, obesity, insulin resistance), hormonal (low testosterone, thyroid dysfunction), neurological (diabetic neuropathy, post-prostatectomy nerve damage), medication side effects (antihypertensives, antidepressants, opioids), psychological (anxiety, depression, performance anxiety), and sleep disorders (obstructive sleep apnoea).

Do PDE5 inhibitors (Viagra, Cialis) always work?

PDE5 inhibitors work in approximately 70% of men. They are less effective in severe vascular disease, in men with very low testosterone, and in diabetes with significant autonomic neuropathy. They require sexual stimulation to work — they do not cause erection independently. Men who do not respond to one agent may respond to another, a different dose, or a combination approach.

Can erectile dysfunction be reversed?

In many men, yes. Regular aerobic exercise, weight loss, smoking cessation, blood pressure and glucose control, treatment of sleep apnoea, and reduced alcohol use all improve erectile function — often significantly. For medication-related ED, switching agents frequently resolves the problem. Medical treatments (PDE5 inhibitors, testosterone therapy where appropriate) are effective for most men with persistent ED.

Erectile Dysfunction — Causes, Cardiovascular Risk, and Treatment

Erectile Dysfunction Is a Vascular Issue

Erectile dysfunction — the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity — affects approximately 40% of men over 40, with prevalence rising sharply with age. But the common framing of ED as a sexual problem, or as a matter of embarrassment, misses something clinically important.

An erection is a vascular event. It requires nitric oxide release from healthy vascular endothelium, arterial dilation, and blood flow into the corpora cavernosa of the penis. The same endothelial biology, the same risk factors, and the same pathological process — atherosclerosis — govern blood flow through coronary and cerebral arteries.

The penile arteries (1–2 mm diameter) are smaller than the coronary arteries (3–4 mm). Atherosclerosis affects smaller vessels earlier. This is why ED typically precedes a cardiac event by 3–5 years in men with shared vascular risk factors. A man who develops new ED at age 52 without a clear psychological cause is not simply experiencing a sexual problem — he may be experiencing an early warning sign of cardiovascular disease.

Treating ED without assessing cardiovascular risk misses a critical prevention opportunity.

How Erections Work

Understanding why erections fail requires understanding how they occur:

Sexual arousal activates the parasympathetic nervous system
Nitric oxide (NO) is released from vascular endothelial cells and nerve terminals in the penis
NO stimulates production of cGMP (cyclic guanosine monophosphate), which causes smooth muscle relaxation in penile arteries and the corpora cavernosa
Arterial blood flows in; the corpora expand and compress penile veins
Sustained pressure maintains rigidity

Disruption at any step produces ED. Atherosclerosis reduces arterial flow. Endothelial dysfunction reduces nitric oxide. Diabetic neuropathy disrupts nerve signalling. Performance anxiety activates the sympathetic nervous system, which counteracts parasympathetic erectile response. Smoking acutely impairs nitric oxide release.

Causes of Erectile Dysfunction

1. Vascular Disease

Atherosclerosis, hypertension, and dyslipidaemia reduce endothelial function and penile blood flow. The cardiovascular risk factors that drive coronary artery disease drive ED through identical mechanisms:

Hypertension — damages endothelium, reduces arterial compliance, and impairs nitric oxide production
Dyslipidaemia — elevated LDL and low HDL promote penile arterial plaque
Smoking — acutely reduces nitric oxide and chronically damages the vascular lining; smoking approximately doubles the risk of ED
Age — endothelial function declines progressively; arterial stiffness increases

Vascular ED is the most common cause in men over 50. It is often gradual in onset, present in all contexts (not situational), and associated with absent or reduced morning erections.

2. Type 2 Diabetes

Diabetes causes ED through multiple simultaneous pathways:

Microvascular disease — small vessel damage impairs penile arterial perfusion
Autonomic neuropathy — disrupts parasympathetic nerve signals required for smooth muscle relaxation
Endothelial dysfunction — elevated blood glucose directly damages the vascular endothelium
Secondary hypogonadism — diabetes is associated with reduced testosterone

ED affects approximately 50–75% of men with type 2 diabetes — often earlier, more severely, and with a poorer response to oral medication than in non-diabetic men. Good glycaemic control (maintaining HbA1c in target range) slows the progression of both vascular and neuropathic damage.

See Type 2 Diabetes — Overview and Management.

3. Obesity

Obesity contributes to ED through several overlapping mechanisms:

Increased aromatisation of testosterone to oestrogen in adipose tissue, lowering free testosterone
Insulin resistance and metabolic syndrome
Elevated inflammatory cytokines that impair endothelial function
Obstructive sleep apnoea (itself an independent cause of ED)
Physical deconditioning and reduced cardiovascular fitness

Men who lose 10% or more of body weight demonstrate clinically significant improvements in erectile function — independent of any change in testosterone. Weight loss through lifestyle change, GLP-1 medications, or bariatric surgery all show benefit. See Obesity and Metabolic Health Hub.

4. Obstructive Sleep Apnoea

Sleep apnoea impairs erectile function through multiple pathways:

Intermittent hypoxaemia — repeated oxygen desaturations during apnoeic episodes damage endothelial function
Nocturnal testosterone suppression — testosterone is secreted primarily during deep sleep; sleep fragmentation impairs this
Sympathetic activation — apnoeas trigger adrenaline release that causes vasoconstriction and suppresses parasympathetic erectile response
Metabolic consequences — sleep apnoea independently drives insulin resistance and hypertension

CPAP treatment of sleep apnoea improves erectile function in many men, independent of testosterone changes. Men with ED and prominent snoring, witnessed apnoeas, excessive daytime sleepiness, or a morning headache should be assessed for sleep apnoea before assuming another cause. See Sleep Apnoea — Causes, Risks, and Treatment.

5. Low Testosterone

Testosterone is required for normal libido, contributes to penile smooth muscle health, and supports nitric oxide production. However, low testosterone as a primary cause of ED — isolated from other vascular or metabolic risk factors — is less common than widely assumed.

Many men with low testosterone have underlying obesity, sleep apnoea, or chronic illness driving both the hormonal decline and the ED. Addressing the root cause often improves both simultaneously. Testosterone therapy improves erectile function in confirmed hypogonadal men, but does not substitute for evaluating and treating vascular risk factors.

If testosterone deficiency is suspected (low libido, fatigue, reduced morning erections, muscle loss), request a morning serum testosterone — levels are highest between 7–10am. See Testosterone Replacement Therapy and Natural Testosterone Optimisation.

6. Medications

Many commonly prescribed medications impair erectile function:

Drug class	Common examples	Mechanism
Older antihypertensives	Thiazides, non-selective beta-blockers	Haemodynamic effects, altered lipid/hormone profile
Antidepressants	SSRIs, SNRIs, TCAs	Serotonergic suppression of libido and ejaculation
Anti-androgens	Spironolactone, bicalutamide	Testosterone receptor blockade
5-alpha reductase inhibitors	Finasteride, dutasteride	Reduced dihydrotestosterone (DHT)
Opioids	Codeine, oxycodone, morphine	Suppress gonadotrophin and testosterone
H2 blockers	Cimetidine	Anti-androgenic effect
Antipsychotics	Many agents	Hyperprolactinaemia; dopamine blockade

Do not stop prescribed medication without speaking to your doctor. Many alternatives exist. Newer antihypertensives (ARBs, ACE inhibitors, calcium channel blockers) are substantially less likely to cause ED than thiazides and older beta-blockers. Among antidepressants, bupropion and mirtazapine have the lowest rates of sexual side effects; SSRIs vary — switching from paroxetine to sertraline or escitalopram may help.

7. Psychological and Relationship Factors

Anxiety, depression, performance anxiety, and relationship stress are significant contributors to ED — and interact with physical causes. A man who experiences ED due to a physical cause may develop secondary performance anxiety that perpetuates and amplifies the problem.

Psychological ED is more common in:

Younger men (under 40) without vascular risk factors
Men with situational ED (present with a partner but absent during masturbation)
Men with preserved normal nocturnal or morning erections
Men with onset after a specific stressful event

Performance anxiety is the most common psychological cause and typically presents as inability to achieve erection with a partner, normal erections in other contexts, and significant anticipatory anxiety. See Male Mental Health — Depression, Help-Seeking, and Wellbeing and Depression — Symptoms, Causes, and Treatment.

8. Neurological Causes

The nerve pathways required for erection can be disrupted by:

Diabetic autonomic neuropathy (most common)
Post-radical prostatectomy nerve damage (extremely common; 30–90% of men at 12 months depending on technique)
Pelvic radiation for prostate or rectal cancer
Multiple sclerosis
Parkinson’s disease
Spinal cord injury

Post-prostatectomy ED may be partial or complete, and recovery — where it occurs — typically takes 12–24 months. Penile rehabilitation (early use of PDE5 inhibitors to maintain tissue oxygenation) is recommended to preserve erectile tissue during nerve recovery. See Prostate Cancer — Guide Hub.

Assessment: When and How to Seek Help

Seek a GP assessment if ED:

Is persistent (present on most attempts over 3 or more months)
Is new or significantly worsening
Occurs in a man under 60 without an obvious psychological explanation
Is accompanied by reduced libido, fatigue, loss of morning erections, or muscle loss (suggesting testosterone deficiency)
Occurs alongside urinary symptoms, testicular changes, or pelvic pain

What your doctor will assess:

Duration, onset (sudden or gradual), and pattern (all contexts or situational)
Presence of morning erections (a useful indicator of vascular vs. psychological cause)
Cardiovascular risk factors: smoking, blood pressure, cholesterol, diabetes, family history
Current medications
Sleep quality, snoring, daytime sleepiness
Mood, stress levels, relationship factors
Alcohol and substance use

Investigations typically include:

Fasting blood glucose and HbA1c
Fasting lipid profile
Morning testosterone (if symptoms suggest hypogonadism)
Blood pressure measurement
In selected men: LH, FSH, prolactin (if hypogonadism confirmed), thyroid function

The Princeton Consensus: ED and Cardiac Risk

The Princeton Consensus guidelines — the standard international framework for managing ED in men with cardiovascular disease — stratify men into three groups:

Low cardiac risk — no cardiac symptoms, stable coronary disease, good exercise tolerance (can climb two flights of stairs without chest pain or dyspnoea). Can initiate ED treatment without further cardiac investigation.
Intermediate cardiac risk — moderate stable angina, recent MI (within 6 weeks but more than 2 weeks), or multiple cardiovascular risk factors. Requires further cardiovascular assessment before ED treatment; exercise stress testing may be appropriate.
High cardiac risk — unstable angina, severe heart failure, recent MI (within 2 weeks), uncontrolled hypertension, significant arrhythmia. ED treatment deferred until cardiac condition is stable.

Men with ED and intermediate cardiovascular risk — common in clinical practice — benefit from a structured cardiovascular risk assessment before initiating therapy. See Cardiovascular Risk Assessment — Beyond Cholesterol.

Treatment

1. Lifestyle Modification — First Line

The evidence for lifestyle modification in ED is substantial and underappreciated:

Regular aerobic exercise (30 minutes, 5 days/week): improves endothelial function, reduces weight, lowers blood pressure, and raises testosterone — one of the most effective ED interventions; some studies show benefit comparable to PDE5 inhibitors
Weight loss: 10% weight reduction improves erectile function significantly in obese men; results are independent of testosterone change
Smoking cessation: penile blood flow improves measurably within months; effect is dose-dependent with the number of years smoked
Reduced alcohol: chronic heavy alcohol consumption suppresses testosterone and impairs neurological function; moderate reduction shows rapid benefit
Blood pressure and glucose control: slows vascular and neuropathic damage
Sleep apnoea treatment: CPAP improves ED in many men with sleep-disordered breathing

2. PDE5 Inhibitors — First-Line Medical Treatment

Phosphodiesterase type 5 (PDE5) inhibitors work by blocking the enzyme that breaks down cGMP, prolonging smooth muscle relaxation in penile vessels. They require sexual stimulation and do not produce erection independently.

Drug	Duration of action	Key notes
Sildenafil (Viagra, generic)	4–6 hours	Take 1 hour before; high-fat meals delay absorption
Tadalafil (Cialis, generic)	24–36 hours	Available as daily low-dose (5 mg) for continuous coverage
Vardenafil (Levitra)	4–6 hours	Similar efficacy and profile to sildenafil
Avanafil (Spedra)	2–4 hours	Fastest onset; fewer colour-vision side effects

Absolute contraindication: PDE5 inhibitors combined with nitrate medications (GTN spray, nitrate patches, isosorbide mononitrate/dinitrate) cause potentially fatal hypotension. Men taking nitrates for angina cannot safely use PDE5 inhibitors.

Caution with: alpha-blockers (hypotension risk), grapefruit juice (increases drug levels), recent stroke or MI.

Approximately 70% of men respond to PDE5 inhibitors. Response rates are lower in diabetic neuropathy, severe vascular disease, and post-prostatectomy ED. Men who do not respond to one agent may respond to another or to a higher dose.

Generic sildenafil and tadalafil are widely available in Australia at significantly lower cost than branded versions.

3. Testosterone Therapy

For men with confirmed hypogonadism (low morning testosterone on two separate tests), testosterone therapy improves libido and often improves erectile function. In men with borderline testosterone, the combination of testosterone supplementation with a PDE5 inhibitor may be more effective than either alone.

Testosterone therapy is not appropriate for men with normal testosterone levels, and does not replace assessment of vascular risk factors — in many men, treating the underlying cause of testosterone suppression (obesity, sleep apnoea) restores both testosterone and erectile function without supplementation.

4. Psychological Therapy

Psychosexual therapy and cognitive-behavioural therapy (CBT) are effective for ED with a significant psychological component, particularly performance anxiety. Therapy may be delivered individually or with a partner. Even where ED has a physical cause, psychological support helps manage the anxiety and relationship stress that frequently develop secondarily.

5. Vacuum Erection Device

A vacuum erection device uses negative pressure to draw blood into the penis, followed by a constriction ring to maintain rigidity. Non-invasive, medication-free, and effective in approximately 90% of men regardless of cause. Particularly useful when PDE5 inhibitors are contraindicated (e.g. nitrate use) or poorly tolerated.

6. Intracavernosal Injection Therapy

Alprostadil (prostaglandin E1) injected directly into the corpora cavernosa produces erection within 10–15 minutes, independent of arousal. Highly effective (80–90% of men) and preferred for neurogenic and severe vasculogenic ED where oral therapy is insufficient. Requires instruction in self-injection technique. Priapism (erection lasting more than 4 hours) is a rare but serious complication requiring emergency treatment.

7. Intraurethral Alprostadil (MUSE)

A small alprostadil pellet inserted into the urethra is absorbed locally. Less effective than injection therapy; preferred by men who cannot tolerate needles. Often used with a constriction ring to improve retention.

8. Penile Prosthesis

Surgical implantation of a penile prosthesis (inflatable or semi-rigid) is the definitive treatment for severe, medication-refractory ED. Patient satisfaction rates are very high (>90%) despite the irreversible nature of the procedure. Appropriate for men in whom all other approaches have failed.

9. Low-Intensity Shockwave Therapy (LI-ESWT)

A non-invasive treatment delivering low-energy acoustic waves to penile tissue to stimulate neovascularisation and endothelial repair. Growing evidence for mild to moderate vasculogenic ED, particularly in men who respond poorly to PDE5 inhibitors. Not widely available in Australia and not covered by Medicare. May offer benefit in selected men as a complement or alternative to oral therapy.

ED After Prostate Cancer Treatment

Erectile dysfunction following radical prostatectomy occurs in 30–90% of men at 12 months, even with nerve-sparing techniques. Recovery of function, where it occurs, takes 12–24 months. Penile rehabilitation — early use of low-dose daily PDE5 inhibitors (tadalafil 5 mg daily) to maintain tissue oxygenation and smooth muscle integrity during nerve recovery — is recommended by most urological guidelines and should be initiated within weeks of surgery. See Prostate Cancer — Guide Hub.

Educational only; not a substitute for professional medical advice.